Nosium

What Nosium does

Nosium — now operating as Medicortex International AB (publ) following a reverse acquisition completed June 30, 2026 — was originally founded in 2015 in Stockholm as a venture builder listed on the NGM Growth Market under ticker NOSIUM. In its prior form, it invested in and provided strategic/operational support to a small portfolio of Nordic growth companies (Co-properties at 5.49%, fully-owned Invest Riddarholmen 1802, fully-owned Dr Sannas Sweden, NOSIUM Consulting, and a 0.39% stake in Dividend Sweden AB), generating revenue via dividends, capital gains on share sales, and consulting fees. Following the November 2025 Share Purchase Agreement and June 2026 completion, the company acquired 89.9% of Medicortex Finland Oyj and was renamed Medicortex International AB (publ), with ticker changing to MEDFIN from July 1, 2026.

The post-transformation entity focuses on non-invasive diagnostics for traumatic brain injury (TBI). Its core product, ProbTBI, is a saliva/urine-based test that detects glycans released when brain cells are damaged, delivering results within minutes without blood draws, hospital equipment, or radiation. The technology is supported by 9 granted patents in glycan-based detection held by Medicortex Finland Oyj, with a complementary saliva-based test (IndicateTBI) under development. The company targets the global TBI diagnostics market projected to reach $3.3 billion by 2029, addressing 69 million TBI cases annually (90% mild TBI). Market launch is planned for 2028, with a projected revenue forecast of up to 15 million EUR by 2032. The US Department of Defense has provided three grants totaling 4.9 million EUR to validate the technology for military and mass-casualty applications.

The combined entity operates with 1-10 employees from a single Stockholm headquarters (Artillerigatan 6, 114 51 Stockholm), with Adrian Harel (PhD, MBA, founder of Medicortex Finland) as CEO, Anna Tenstam as Chairman, and board members including Nils Grönberg, Ville Ranta-Panula, and Jesper Yrwing. Distribution occurs through public equity channels (Avanza and Nordnet platforms via NGM listing) and partnership with Nordic Certified Adviser AB for exchange compliance. The corporate trajectory represents a full strategic pivot from a Nordic minority-stake venture builder into a pre-commercial medtech diagnostics developer, with the legacy portfolio retained for now but secondary to the new core business.

Name

Nosium

Legal name

NOSIUM AB (publ)

Website

https://nosium.com

Company type

Public

Founded year

2015

Operating status

Operating

Headcount range

1–10 employees

Short description

Medicortex International AB (formerly Nosium) is a Stockholm-listed public company developing ProbTBI, a non-invasive saliva/urine diagnostic test for traumatic brain injury, built on patented glycan-detection technology acquired via reverse takeover of Medicortex Finland Oyj in June 2026.

Ownership category

akta.pro rank

Product category

Venture Capital and Investment Management

NAICS

Research and Development in Biotechnology (except Nanobiotechnology) (541714), Scientific Research and Development Services (5417)

SIC

Services-Commercial Physical & Biological Research (8731), Surgical & Medical Instruments & Apparatus (3841)

akta.pro primary industry

Genomics & Next-Generation Sequencing (NGS) Services (HLAGANAA)

Keywords

• Venture building
• Investment holdings
• Portfolio management
• Growth equity investing
• Diagnostic test development

Headquarters

HQ city

Stockholm

HQ country

Sweden

HQ region

Europe

Offices1 record

Markets served

GTM type

B2B

Offering type

Services

Cost components

Personnel, Operations, Marketing or Sales, Technology or R&D, Others

Revenue model

1. Dividend income from portfolio companies: Long-term revenue through dividends from portfolio company holdings. The company holds stakes in multiple portfolio companies including Co-properties (5.49%), Dividend Sweden AB (0.39%), and fully owned NOSIUM Consulting.
2. Capital gains from share sales: Revenue from selling shares in portfolio companies. NOSIUM intends to long-term generate returns through the sale of shares in portfolio companies.
3. Consulting fees from portfolio companies: Revenue from consulting work performed in portfolio companies. NOSIUM generates long-term revenue through consulting fees for work performed in portfolio companies.

Go-to-market motion1 record

Distribution channels2 records

Marketing channels6 records

Core offering

NOSIUM is a Swedish venture builder that invests in entrepreneurs and high-growth potential companies by acquiring, owning, and managing equity stakes, while providing strategic and operational support to significantly increase the market value of portfolio companies within 12 months. The company generates long-term revenue through dividends, capital gains from share sales, and consulting fees from its portfolio companies. Following a reverse acquisition of Medicortex Finland Oyj completed in June 2026, the company has transitioned to also develop ProbTBI, a non-invasive diagnostic test for traumatic brain injuries.

Product overview

NOSIUM is a venture builder investment company that transitioned to become Medicortex International AB (publ) following a reverse acquisition of Medicortex Finland Oyj in 2025-2026. The company's primary product focus is now ProbTBI, a non-invasive diagnostic test for traumatic brain injuries. Prior to the transformation, NOSIUM operated as an investment vehicle with portfolio companies including Co-properties, Invest Riddarholmen 1802, Dividend Sweden AB (publ), Dr Sannas Sweden, and NOSIUM Consulting. The company also facilitates NOSIUM Network, an exclusive investor network for shareholders. The stock trades on NGM Growth Market under ticker MEDFIN.

Differentiator

Problem solved

Functional benefit

Brands

• ProbTBI™: Non-invasive diagnostic test for traumatic brain injuries (TBI) using saliva or urine samples
• IndicateTBI

Products and services

• NOSIUM Venture Building Service
• NOSIUM Consulting

Segments2 records

Ideal customer profiles2 records

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Partnerships

Seven partnerships are on record, tiered minor.

• AvanzaminorChannel Partner/ Reseller/ DistributorAvanza is a Swedish online trading platform where NOSIUM shares can be followed and traded. Listed as a partner platform for stock information and investment in NOSIUM.
• NordnetminorChannel Partner/ Reseller/ DistributorNordnet is a Swedish online trading platform where NOSIUM shares can be followed and traded. Listed as a partner platform for stock information and investment in NOSIUM.
• Co-propertiesminorOthersNOSIUM holds 5.49% ownership stake in Co-properties (book value 8.8 MSEK). Co-properties is a portfolio company operating in the real estate/property sector.
• Invest Riddarholmen 1802minorOthersNOSIUM holds 100% ownership in Invest Riddarholmen 1802 (book value 5.1 MSEK). Property investment company.
• Dr Sannas Sweden ABminorOthersNOSIUM holds an ownership stake in Dr Sannas Sweden AB (book value 0.9 MSEK). Company focused on natural and organic health products made in Sweden.
• Dividend Sweden AB (publ)minorOthersNOSIUM holds 0.39% ownership (0.37% votes, book value 0.15 MSEK) in Dividend Sweden AB, an investment company that invests in smaller listed Nordic growth companies.
• NOSIUM ConsultingminorOthersNOSIUM fully owns NOSIUM Consulting (book value 0.32 MSEK), providing consulting services to portfolio companies and generating revenue through professional services fees.

Scale indicators7 records

Recent moves7 records

Expansion highlights5 records

Direct peers

• Quanterix: Ultra-sensitive protein biomarker detection platform with neurodegeneration and TBI research applications. Closely comparable as a biomarker-based specialty diagnostics company targeting neurological indications.
• Biodesix: Specialty diagnostics company developing non-invasive blood-based tests for lung disease. Comparable small-cap specialty diagnostics with multi-year development runway and biomarker-driven product strategy.
• T2 Biosystems: Developer of rapid diagnostic panels for sepsis and other conditions using novel biomarker detection. Comparable small-cap rapid-diagnostic peer with similar regulatory pathway and reagent-based economics.
• Trinity Biotech: Specialty diagnostics developer focused on point-of-care and clinical laboratory immunoassays. Comparable small-cap specialty diagnostics business with similar regulatory pathway and product-type economics.
• Immunovia: Swedish-listed specialty diagnostics company developing blood-based tests for early cancer detection. Closely comparable small Nordic diagnostics peer pursuing novel biomarker-based blood/serum tests with similar regulatory and commercialization profile.

Broad incumbents

• GenMark Diagnostics (Roche): Molecular diagnostics company (now part of Roche) developing rapid syndromic panels for hospital and emergency settings. Comparable as a peer in rapid ER/point-of-care diagnostics where TBI testing would also be deployed.
• Abbott Laboratories: Major diagnostics incumbent with broad point-of-care and core-lab menu including i-STAT. Comparable as a potential acquirer/benchmark for the point-of-care TBI diagnostic category Medicortex is targeting.
• Bio-Rad Laboratories: Life science research and clinical diagnostics company with specialty assay and instrument portfolio. Comparable as a broader diagnostics player whose specialty assay segment overlaps with Medicortex's biomarker-detection approach.
• QuidelOrtho: Specialty diagnostics company spanning infectious disease, women's health, and rapid point-of-care tests. Comparable as a peer in rapid, non-invasive diagnostics targeting decentralized clinical settings.

Regional players

• Abacus Diagnostica: Finnish-Nordic molecular diagnostics company focused on rapid point-of-care tests. Comparable as a Nordic regional peer pursuing rapid decentralized diagnostics, with similar geographic and clinical setting overlap.

Market position

Strengths4 records

Weaknesses5 records

Competitive moat5 records

Key risks6 records

Key highlights6 records

Customer concentration

• LinkedInlinkedin.com/company/nosium
• Facebookfacebook.com/nosiumb

Revenue estimate

Valuation estimate

Number of profiles

Profiles4 records

Subsidiaries3 records

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A1 record

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Nosium